Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Behandling av aterosklerotisk njurartärstenos i förändring. Lågdos ACE-hämmare och angiotensin- receptorblockare motiverat i vissa fall.

Alhadad, Alaa LU ; Sterner, Gunnar LU and Herlitz, Hans (2009) In Läkartidningen 106(44). p.8-2840
Abstract
Renovascular hypertension (RVH) is the direct consequence of renal artery stenosis (RAS).

Most RAS patients have dis¬seminated atherosclerosis, with > 6 times greater risk of cardiovascular death than age-matched controls. Elevated levels of angiotensin II and aldosterone lead to detrimental effects both through hypertensive injury and activation of profibrotic and atherosclerotic pathways. The recent primary report from the ASTRAL study supports the conservative treatment in patients with non-severe RAS (on average 2.8 antihypertensive drugs). Consequently, many patients with RVH will be candidates for ACE inhibitor /ARB. In patients at risk of atherosclerotic RAS, treatment with ACE inhibitors may cause acute renal failure... (More)
Renovascular hypertension (RVH) is the direct consequence of renal artery stenosis (RAS).

Most RAS patients have dis¬seminated atherosclerosis, with > 6 times greater risk of cardiovascular death than age-matched controls. Elevated levels of angiotensin II and aldosterone lead to detrimental effects both through hypertensive injury and activation of profibrotic and atherosclerotic pathways. The recent primary report from the ASTRAL study supports the conservative treatment in patients with non-severe RAS (on average 2.8 antihypertensive drugs). Consequently, many patients with RVH will be candidates for ACE inhibitor /ARB. In patients at risk of atherosclerotic RAS, treatment with ACE inhibitors may cause acute renal failure 1-14 days after the initiation of treatment with ACE inhibitors. Determination of serum creatinine is obligatory within two weeks after the administration of ACEi/AII blockers in patients with suspected RVH. In patients with severe hypertension in the presence of other atherosclerotic manifestations unilateral renal artery stenosis should be suspected and further investigated before treatment with ACEi/ARB is initiated. (Less)
Please use this url to cite or link to this publication:
author
; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Renovascular: etiology, Angiotensin-Converting Enzyme Inhibitors: therapeutic use, Angiotensin II Type 1 Receptor Blockers: administration & dosage, Antihypertensive Agents: therapeutic use, Atherosclerosis: drug therapy, Atherosclerosis: therapy, Renovascular: drug therapy, Hypertension, Renal Artery Obstruction: complications, Renal Artery Obstruction: drug therapy, Renal Artery Obstruction: therapy
in
Läkartidningen
volume
106
issue
44
pages
8 - 2840
publisher
Swedish Medical Association
external identifiers
  • pmid:19967962
  • scopus:70350610970
ISSN
0023-7205
language
Swedish
LU publication?
yes
id
b4fbe5da-40ed-4151-8833-a18b742b3c39 (old id 1523860)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/19967962?dopt=Abstract
http://ltarkiv.lakartidningen.se/artNo37204
date added to LUP
2016-04-04 09:36:32
date last changed
2022-01-29 18:43:16
@article{b4fbe5da-40ed-4151-8833-a18b742b3c39,
  abstract     = {{Renovascular hypertension (RVH) is the direct consequence of renal artery stenosis (RAS).<br/><br>
Most RAS patients have dis¬seminated atherosclerosis, with &gt; 6 times greater risk of cardiovascular death than age-matched controls. Elevated levels of angiotensin II and aldosterone lead to detrimental effects both through hypertensive injury and activation of profibrotic and atherosclerotic pathways. The recent primary report from the ASTRAL study supports the conservative treatment in patients with non-severe RAS (on average 2.8 antihypertensive drugs). Consequently, many patients with RVH will be candidates for ACE inhibitor /ARB. In patients at risk of atherosclerotic RAS, treatment with ACE inhibitors may cause acute renal failure 1-14 days after the initiation of treatment with ACE inhibitors. Determination of serum creatinine is obligatory within two weeks after the administration of ACEi/AII blockers in patients with suspected RVH. In patients with severe hypertension in the presence of other atherosclerotic manifestations unilateral renal artery stenosis should be suspected and further investigated before treatment with ACEi/ARB is initiated.}},
  author       = {{Alhadad, Alaa and Sterner, Gunnar and Herlitz, Hans}},
  issn         = {{0023-7205}},
  keywords     = {{Renovascular: etiology; Angiotensin-Converting Enzyme Inhibitors: therapeutic use; Angiotensin II Type 1 Receptor Blockers: administration & dosage; Antihypertensive Agents: therapeutic use; Atherosclerosis: drug therapy; Atherosclerosis: therapy; Renovascular: drug therapy; Hypertension; Renal Artery Obstruction: complications; Renal Artery Obstruction: drug therapy; Renal Artery Obstruction: therapy}},
  language     = {{swe}},
  number       = {{44}},
  pages        = {{8--2840}},
  publisher    = {{Swedish Medical Association}},
  series       = {{Läkartidningen}},
  title        = {{Behandling av aterosklerotisk njurartärstenos i förändring. Lågdos ACE-hämmare och angiotensin- receptorblockare motiverat i vissa fall.}},
  url          = {{http://www.ncbi.nlm.nih.gov/pubmed/19967962?dopt=Abstract}},
  volume       = {{106}},
  year         = {{2009}},
}